A site-specific polymeric drug carrier for renal disease treatment.
A well-designed polymeric carrier for site-specific drug delivery in the treatment of renal disease has been reported recently. Approximately 80% of the water-soluble polymer poly(vinylpyrrolidone-co-dimethyl maleic anhydride selectively accumulated in the kidney of mice 24 h after intravenous injection. The detailed mechanism of such selective accumulation is not clear but an energy-dependent process, other than endocytosis, might be involved in the uptake of the polymer. This study is the first to report active targeting using a synthetic polymeric drug carrier.
Kishida
Akio
A
Department of Biomedical Engineering, National Cardiovascular Center Research Institute, 5-7-1 Fujishiro-dai, Suita, 565-8565, Osaka, Japan. kishida@ri.ncvc.go.jp
D000818:Animals; D004337:Drug Carriers / Q000737:chemistry / Q000493:pharmacokinetics*; D007668:Kidney / Q000378:metabolism*; D007674:Kidney Diseases / Q000188:drug therapy; D051379:Mice; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry / Q000493:pharmacokinetics; D011759:Pyrrolidines / Q000737:chemistry / Q000493:pharmacokinetics*; D013678:Technology, Pharmaceutical; D014753:Vinyl Compounds / Q000737:chemistry / Q000493:pharmacokinetics*
D004337:Drug Carriers; D004364:Pharmaceutical Preparations; D011759:Pyrrolidines; D014753:Vinyl Compounds; C475304:poly(vinylpyrrolidone-co-dimethyl maleic anhydride); D011092:Polyethylene Glycols